

# Endosense Closes USD 36 Million / Euro 25 Million Series B Financing

September 01, 2009 07:00 AM Eastern Daylight Time

GENEVA--(BUSINESS WIRE)--Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. The financing will primarily be used to fund the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company's proprietary force-sensing ablation catheter, the [TactiCath®](#).

"We believe that Endosense's TactiCath is uniquely positioned to greatly improve the treatment of cardiac arrhythmias, a series of life-threatening disorders that affect millions of patients worldwide," said Dr. Olivier Litzka, partner at EdRIP. "Ablation is one of the highest-growth markets in the cardiovascular space. Force measurement during the ablation procedure has become a prime object of interest to improve safety and efficacy for patients. As Endosense with its proprietary force-sensing technology is the clear leader in this field, this represents an excellent investment opportunity to us."

**"We believe that Endosense's TactiCath is uniquely positioned to greatly improve the treatment of cardiac arrhythmias, a series of life-threatening disorders that affect millions of patients worldwide"**

As part of the Series B activity, Endosense has made several board appointments to reflect its new shareholder mix. EdRIP Partner Olivier Litzka, Gimv Executive Vice President Life Sciences Patrick van Beneden and VI Partner Diego Braguglia have become directors.

"This \$36 million financing is a major achievement for Endosense," said Eric Le Royer, president and chief executive officer, Endosense. "We believe this investment speaks to the potential of our force-sensing technology and the tremendous clinical value it is anticipated to provide to physicians and patients."

Granted the [CE mark](#) in May 2009, Endosense's TactiCath is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone [considerable pre-clinical and clinical testing](#), the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.

The TactiCath has the potential to improve the effectiveness, safety and reproducibility of catheter ablation treatment of cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting more than six million people worldwide. Currently, most AF patients are treated with pharmaceutical drugs that do not address the underlying cause and have side effects, with invasive ablation surgery as the primary treatment alternative. Endosense is focused on providing this sizeable patient population with a minimally invasive treatment option that is both safe and effective. The overall market for AF treatments represents a multi-billion dollar opportunity. The current worldwide market for catheter ablation is valued at more than 500 million dollars. The atrial fibrillation ablation market has been growing at a rate of over 50 percent for the past five years. Double-digit market growth is expected to continue for the next five to 10 years, driven by an aging population and safer, more effective and more widely performed ablation procedures.

## About Edmond de Rothschild Investment Partners

Paris-based Edmond de Rothschild Investment Partners (EdRIP) is dedicated to minority investments into privately-owned companies. It has currently more than Euro 750 million under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Science Team of seven professionals has over 90 years of cumulated experience in the life science industry and has a proven track record in biotechnology and medical technology investments. The team has approximately Euro 270 million under management, recently raised its Euro 155 million BioDiscovery 3 fund, which is to be invested during the next years. Edmond de Rothschild Investment Partners is part of the group La Compagnie Financière Edmond de Rothschild.

For more information, visit <http://www.edrip.fr>

## About Neomed

NeoMed Management is an international investment management firm, based in Oslo, Geneva and Boston specializing in the health care and life sciences industry. NeoMed's funds invest in innovative, development stage companies that have the potential to achieve exceptional growth driven by innovative products. Portfolio companies typically develop improved therapeutics, diagnostics or devices for the treatment of medical needs that are currently unmet or poorly served.

For more information, visit <http://www.neomed.no/>

**About Gimv** - For more information, visit <http://www.gimv.com>

**About VI Partners** - For more information, visit <http://www.vipartners.ch>

**About Sectoral Asset Management** - For more information, visit <http://www.sectoral.com>

**About Ysios** - For more information, visit <http://www.ysioscapital.com>

**About Initiative Capital Romandie** - For more information, visit <http://www.defigestion.ch>

## About Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary [Touch+® sensor technology](#). Endosense's flagship product is the TactiCath®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

For more information, visit <http://www.endosense.com>

## Contacts

MEDIA CONTACT/U.S.:

Nobles Communications

Laura Nobles

310-795-0497

[laura@noblescommunications.com](mailto:laura@noblescommunications.com)

or

MEDIA CONTACT/EUROPE:

Genevensis

Danièle Castle

+41 22 779 06 20

[info@genevensis.com](mailto:info@genevensis.com)